Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer

Journal article

Peer reviewed

F.A Holmes

Journal of clinical oncology, Vol.20(3), pp.727-731

2002-02-01

PMID: 11821454

Metrics

6 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.103 Blood Disorders; 1.103.606 Hematopoietic Stem Cells
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer
Creators: F.A Holmes
Publication Details: Journal of clinical oncology, Vol.20(3), pp.727-731
Language: English
Resource Type: Journal article
PMID: 11821454
Record Identifier: 991031613360702976